Biologic therapies in the treatment of psoriasis: A comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring

Clinical Reviews in Allergy and Immunology

Volumn 44, Issue 2, 2013, Pages 121-140

  Sivamani, Raja K ^a   Goodarzi, Heidi ^a   Garcia, Miki Shirakawa ^a   Raychaudhuri, Siba P ^b   Wehrli, Lisa N ^a,b   Ono, Yoko ^a,b   Maverakis, Emanual ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Abatacept; Adalimumab; Alfecept; Biologics; Briakinumab; Certolizumab; Efalizumab; Etanercept; Golimumab; Infliximab; Psoriasis; Quantiferon; Secukinumab; TNF; Tuberculosis; Ustekinumab

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; BRIAKINUMAB; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; ISONIAZID; METHOTREXATE; PLACEBO; PYRAZINAMIDE; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

BIOLOGICAL THERAPY; CANCER RISK; CELLULITIS; CENTRAL NERVOUS SYSTEM INFECTION; CHEMOPROPHYLAXIS; CHILL; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY DISEASE; DENDRITIC CELL; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERYTHRODERMIC PSORIASIS; EVIDENCE BASED PRACTICE; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; INJECTION SITE REACTION; LATENT TUBERCULOSIS; LONG TERM CARE; META ANALYSIS (TOPIC); MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEUTROPHIL; NONHUMAN; PATIENT MONITORING; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; REVIEW; RHINITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; SCREENING TEST; SIGNAL TRANSDUCTION; SINUSITIS; SKIN CANCER; SKIN PAPILLOMA; STREPTOCOCCAL PHARYNGITIS; T LYMPHOCYTE; TH17 CELL; THERAPY EFFECT; TUBERCULIN TEST; UPPER RESPIRATORY TRACT INFECTION;

EID: 84878623453     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-012-8301-7     Document Type: Review

References (172)

1. Christophers E (2001) Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 26:314-320 (Pubitemid 34204344)
2. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE (1999) Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141:185-191 (Pubitemid 29397982)
3. Zachariae H (2003) Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4:441-447 (Pubitemid 36871763)
4. Strange A et al (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42:985-U106
5. Lew W, Bowcock AM, Krueger JG (2004) Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol 25:295-305 (Pubitemid 38610353)
6. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496-509
7. Schlaak JF et al (1994) T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102:145-149 (Pubitemid 24060399)
8. Zaba LC et al (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204:3183-3194
9. Res PC et al (2010) Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5:e14108
10. Schirmer C, Klein C, von Bergen M, Simon JC, Saalbach A (2010) Human fibroblasts support the expansion of IL-17-producing T cells via up-regulation of IL-23 production by dendritic cells. Blood 116:1715-1725
11. Ghoreschi K et al (2010) Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467:967-U144
12. Wolk K et al (2009) The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 39:3570-3581
13. Nograles KE et al (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159:1092-1102
14. Ma HL et al (2008) IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 118:597-607
15. Winterfield L, Menter A (2004) Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. Dermatol Clin 22:437-447, ix (Pubitemid 39144390)
16. Wolk K et al (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36:1309-1323
17. Zheng Y et al (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648-651 (Pubitemid 46232884)
18. Caruso R et al (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15:1013-1015
19. Wahba A, Cohen H, Bareli M, Callily R (1979) Neutrophil chemotaxis in psoriasis. Acta Derm Venereol 59:441-445 (Pubitemid 10249028)
20. Theoharides TC et al (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107:4448-4453
21. Dubertret L et al (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155:729-736 (Pubitemid 44352553)
22. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS (2005) Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 52:434-444
23. Caporali R et al (2010) Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 9:465-469
24. Fautrel B et al (2007) Recommendations of the French Society for Rheumatology regarding TNF alpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 74:627-637 (Pubitemid 350236029)
25. Spadaro A et al (2010) Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology 49:1107-1111
26. Pitarch G, Sanchez-Carazo JL, Mahiques L, Oliver V (2008) Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 216:312-316 (Pubitemid 351630095)
27. Jamnitski A et al (2011) The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70:284-288
28. Conti F et al (2007) Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 66:1393-1397 (Pubitemid 47492489)
29. Scallon B et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418-426 (Pubitemid 34429950)
30. Barrera P et al (2001) Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 60:660-669 (Pubitemid 32588369)
31. Charles P et al (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163:1521-1528 (Pubitemid 29352775)
32. Suffredini AF et al (1995) Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038-5045
33. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668 (Pubitemid 39506617)
34. Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL (1992) Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149:3881-3888 (Pubitemid 23068868)
35. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K (2001) Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 299:119-129 (Pubitemid 34053400)
36. Eissner G et al (2000) Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 164:6193-6198 (Pubitemid 30408797)
37. Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G (2004) Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28:67-74 (Pubitemid 39295687)
38. Shen C et al (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21:251-258 (Pubitemid 40278362)
39. Mitoma H, Horiuchi T, Tsukamoto H (2004) Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 126:934-935, author reply 935-936 (Pubitemid 38298342)
40. Arora T et al (2009) Differences in binding and effector functions between classes of TNF antagonists. Cytokine 45:124-131
41. Kaymakcalan Z et al (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131:308-316
42. Van den Brande JM et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124:1774-1785 (Pubitemid 36666774)
43. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ (2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50:206-211 (Pubitemid 34087933)
44. Lugering A et al (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121:1145-1157 (Pubitemid 33022095)
45. Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34:12-18
46. Nestorov I (2005) Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74:13-18 (Pubitemid 40365775)
47. St Clair EW et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1451-1459 (Pubitemid 34620190)
48. Caproni M et al (2009) Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 29:210-214
49. Zaba LC et al (2009) Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 124(1022-1010):e1021-e1395
50. Shen H, Xia L, Lu J, Xiao W (2010) Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Investig Med 58:905-908
51. Kageyama Y et al (2007) Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol 26:505-509 (Pubitemid 46359288)
52. Gudbrandsdottir S et al (2004) TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 22:118-124 (Pubitemid 38232819)
53. Crowe PD et al (1994) A lymphotoxin-beta-specific receptor. Science 264:707-710 (Pubitemid 2070849)
54. Ware CF (2005) Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23:787-819 (Pubitemid 40563185)
55. Browning JL et al (1995) Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J Immunol 154:33-46
56. Pujol-Borrell R et al (1987) HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 326:304-306 (Pubitemid 17053756)
57. Chan JR et al (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203:2577-2587 (Pubitemid 44833335)
58. Ye P et al (2001) Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194:519-527 (Pubitemid 32835046)
59. Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248-255 (Pubitemid 32695064)
60. Krueger GG et al (2002) A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47:821-833 (Pubitemid 35403039)
61. Lebwohl M et al (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719-727 (Pubitemid 36705938)
62. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A (2008) Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 159:274-285 (Pubitemid 352009861)
63. Menter A et al (2007) A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56(31):e31-e15
64. Gottlieb AB et al (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51:534-542 (Pubitemid 39278071)
65. Reich K et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367-1374 (Pubitemid 41443403)
66. Hwang WYK, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3-10 (Pubitemid 40558811)
67. Maini RN et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563 (Pubitemid 28459913)
68. Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34:19-22
69. Bendtzen K et al (2006) Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 54:3782-3789 (Pubitemid 44955878)
70. Baert F et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601-608 (Pubitemid 36204954)
71. Tyring S et al (2007) Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143:719-726 (Pubitemid 46955730)
72. Papp KA et al (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152:1304-1312 (Pubitemid 40933433)
73. Paller AS et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358:241-251
74. Leonardi CL et al (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014-2022 (Pubitemid 37448924)
75. Gottlieb AB et al (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627-1632, discussion 1632 (Pubitemid 37523083)
76. Zachariae C et al (2008) The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 88:495-501
77. Gordon KB et al (2006) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55:598-606 (Pubitemid 44436647)
78. Saurat JH et al (2008) Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158:558-566 (Pubitemid 351239154)
79. Menter A et al (2008) Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58:106-115 (Pubitemid 350298146)
80. Kavanaugh A et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976-986
81. Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675-1684 (Pubitemid 351671884)
82. Leonardi CL et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665-1674 (Pubitemid 351671883)
83. Kimball AB et al (2008) Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 144:200-207 (Pubitemid 351287002)
84. Kimball AB et al (2011) Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol 64:263-274
85. Anonymous (Released on October 11, 2010) http://www.abbott.com/global/ url/pressRelease/en-US/Press-Release-0909.htm, Abbot Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874). Last accessed on January 23, 2011
86. Mease P et al (2011) Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 63:939-948
87. www.clinicaltrials.gov. Accessed 25 Nov 2011
88. Silverman D, Oliver A (2011) Abatacept-induced psoriasis. Cutis 88:117-118
89. Kato K, Satoh T, Nishizawa A, Yokozeki H (2011) Psoriasiform drug eruption due to abatacept. Acta Derm Venereol 91:362-363
90. Hueber W et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52ra72
91. Benoit S, Toksoy A, Brocker EB, Gillitzer R, Goebeler M (2004) Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 150:1009-1012 (Pubitemid 38903538)
92. Vieira Serrao V, Martins A, Lopes MJ (2008) Infliximab in recalcitrant generalized pustular arthropatic psoriasis. Eur J Dermatol 18:71-73 (Pubitemid 351158176)
93. Puig L, Barco D, Vilarrasa E, Alomar A (2010) Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review. Dermatology 220:154-158
94. Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S (2006) Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 155:156-159 (Pubitemid 43876409)
95. Fiehn C, Andrassy K (2004) Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Dis 63:232 (Pubitemid 38250662)
96. Lisby S, Gniadecki R (2004) Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venereol 84:247-248 (Pubitemid 38649414)
97. Takahashi MD, Castro LG, Romiti R (2007) Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol 157:828-831 (Pubitemid 47389895)
98. Bissonnette R et al (2008) Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 7:940-946
99. Harty L, Veale DJ (2010) How early should psoriatic arthritis be treated with a TNF-blocker? Curr Opin Rheumatol 22:393-396
100. Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314-J321
101. Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA (2011) Efficacy and safety results from a phase III, randomised controlled trial comparing the safety and efficacy of briakinumab to etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165:661-668
102. Gottlieb AB et al (2011) Efficacy and safety of briakinumab versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 165:652-660
103. Griffiths CE et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118-128
104. Atteno M et al (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29:399-403
105. Saurat JH et al (2011) Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br J Dermatol 165:399-406
106. Hendel L, Hendel J, Johnsen A, Gudmand-Hoyer E (1982) Intestinal function and methotrexate absorption in psoriatic patients. Clin Exp Dermatol 7:491-497 (Pubitemid 12058159)
107. Reich K et al (2010) Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol 63:1011-1018
108. Yazici Y, Adler NM, Yazici H (2008) Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatology (Oxford) 47:1054-1057 (Pubitemid 351865932)
109. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807-811
110. Mann DL et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594-1602 (Pubitemid 38451714)
111. Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57:1885-1888 (Pubitemid 33096700)
112. Gottlieb A et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58:851-864 (Pubitemid 351509657)
113. Menter A et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826-850 (Pubitemid 351509656)
114. Wollina U et al (2008) Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9:1-14
115. Collamer AN, Guerrero KT, Henning JS, Battafarano DF (2008) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 59:996-1001 (Pubitemid 351990997)
116. Ramos-Casals M et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86:242-251 (Pubitemid 47067483)
117. Harrison MJ et al (2009) Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 68:209-215
118. Cope AP et al (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749-760
119. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G (1996) Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184:1397-1411 (Pubitemid 26354696)
120. McDevitt H, Munson S, Ettinger R, Wu A (2002) Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 4(Suppl 3):S141-S152
121. Maverakis E, van den Elzen P, Sercarz EE (2001) Self-reactive T cells and degeneracy of T cell recognition: evolving concepts - from sequence homology to shape mimicry and TCR flexibility. J Autoimmun 16:201-209 (Pubitemid 32566108)
122. Maverakis E et al (2003) Autoreactive T cells can be protected from tolerance induction through competition by flanking determinants for access to class II MHC. Proc Natl Acad Sci USA 100:5342-5347 (Pubitemid 36542707)
123. De Rycke L et al (2005) Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52:2192-2201 (Pubitemid 40994342)
124. Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS (2011) The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol. doi: 10.1007/s12016-010-8248-5
125. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 13:1024-1030 (Pubitemid 47309975)
126. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151-3158 (Pubitemid 35453523)
127. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56:2886-2895 (Pubitemid 47502734)
128. Bongartz T et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285 (Pubitemid 43736578)
129. Maverakis E et al (2010) Light, including ultraviolet. J Autoimmun 34:J247-J257
130. Patel RV, Clark LN, Lebwohl M, Weinberg JM (2009) Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 60:1001-1017
131. Vasiliauskas EA et al (2006) Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 4:1255-1258 (Pubitemid 44512222)
132. Mishkin DS, Van Deinse W, Becker JM, Farraye FA (2006) Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 12:827-828 (Pubitemid 44253768)
133. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2007) Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 46:695-698 (Pubitemid 46523319)
134. Coburn LA, Wise PE, Schwartz DA (2006) The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 51:2045-2047 (Pubitemid 44832588)
135. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36:635-641
136. Solovic I et al (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36:1185-1206
137. Cooper AM, Khader SA (2008) The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 226:191-204
138. Khader SA et al (2005) IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 175:788-795 (Pubitemid 41094960)
139. Gardam MA et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148-155 (Pubitemid 36278124)
140. Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK (2008) Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 59:363-380, quiz 382-364
141. Flynn JL et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572
142. Senaldi G et al (1996) Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 157:5022-5026 (Pubitemid 126449582)
143. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731-740 (Pubitemid 19082507)
144. Keane J et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
145. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122-2127 (Pubitemid 36959191)
146. Dixon WG et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522-528
147. Wallis RS (2011) Biologics and infections: lessons from tumor necrosis factor blocking agents. Infect Dis Clin North Am 25:895-910
148. Doherty SD et al (2008) National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 59:209-217
149. Tsiouri G et al (2009) Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis. Dermatology 219:119-125
150. Brown AJ, Lesher JL Jr (2009) Anti-tumor necrosis factor therapy and interpreting tuberculin skin tests. J Am Acad Dermatol 60:e21-e22
151. Inanc N et al (2009) Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 36:2675-2681
152. Tamborenea MN, Tate G, Mysler E, Debonis J, Schijedman A (2010) Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int 30:613-616
153. Matulis G, Juni P, Villiger PM, Gadola SD (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67:84-90
154. Shovman O et al (2009) QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuber Lung Dis 13:1427-1432
155. Chiu HY, Hsueh PR, Tsai TF (2011) Clinical experience of QuantiFERON((R))-TB gold testing in psoriasis patients treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 164:553-559
156. Diel R et al (2011) Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37:88-99
157. Sester M et al (2011) Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 37:100-111
158. Hamdi H et al (2006) Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114
159. Weinfurter P et al (2011) Predictors of discordant tuberculin skin test and QuantiFERON(R)-TB Gold In-Tube results in various high-risk groups. Int J Tuber Lung Dis 15:1056-1061
160. Carmona L et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766-1772 (Pubitemid 40852885)
161. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF (2005) Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 52:2968-2974 (Pubitemid 41447075)
162. Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62:791 (Pubitemid 36886422)
163. Lim WS, Powell RJ, Johnston ID (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623-626 (Pubitemid 34438827)
164. Gori A, Fabroni C, Prignano F, Lotti T (2010) Unusual presentation of tuberculosis in an infliximab-treated patient - which is the correct TB screening before starting a biologic? Dermatol Ther 23(Suppl 1):S1-S3
165. Huo R, Romanelli P (2010) Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis. Am J Clin Dermatol 11(Suppl 1):39-40
166. Vermeire S et al (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56:1226-1231 (Pubitemid 47300423)
167. Bartelds GM et al (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921-926 (Pubitemid 46999794)
168. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE (2001) Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 26:27-29 (Pubitemid 32204840)
169. Myers W, Christiansen L, Gottlieb AB (2005) Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol 53:S127-S129 (Pubitemid 40961826)
170. Prossick TA, Belsito DV (2006) Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis 78:178-180 (Pubitemid 44484437)
171. Carr D et al (2008) Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatol Treat 19:97-100 (Pubitemid 351891548)
172. Sivamani RK et al (2010) Biological therapy of psoriasis. Indian J Dermatol 55:161-170